Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program
Jounce slashes 57% of staff, drops assets in stock merger with Redx
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
New reports reveals pharma industry social media pioneers
*please scroll down for all the latest news*
